Solid Biosciences Inc. (SLDB) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Solid Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing gene therapy candidates for rare neuromuscular and cardiac diseases. Key pipeline assets include SGT-003 (Duchenne muscular dystrophy), SGT-212 (Friedreich's ataxia), SGT-501 (catecholaminergic polymorphic ventricular tachycardia), and SGT-601 (TNNT2-mediated dilated cardiomyopathy). The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(54,799) | $(39,480) | $(111,536) | $(78,762) |
| Net Loss Per Share (Basic/Diluted) | $(0.38) | $(0.42) | $(0.88) | $(0.98) |
| Operating Expenses | $57,384 | $41,693 | $114,692 | $81,745 |
| Cash & Cash Equivalents | $159,394 (as of June 30, 2026) | |||
| Available-for-Sale Securities | $218,284 (as of June 30, 2026) | |||
| Total Liquidity (Cash + Securities) | $377,678 (as of June 30, 2026) | |||
| Accumulated Deficit | $(1,069,311) (as of June 30, 2026) |
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses rose 37.6% quarter-over-quarter (Q2 2026 vs. Q2 2025) and 40.3% year-to-date. This increase was driven primarily by higher Research and Development (R&D) costs, specifically for the SGT-003 program (manufacturing and clinical costs) and the SGT-212 program (clinical and milestone payments).
- Capital Raising Activity: During the six months ended June 30, 2026, the company raised significant capital through a private placement (March 2026) and at-the-market (ATM) offerings. Net proceeds from the March 2026 Private Placement were approximately $226.3 million, and ATM sales generated $60.8 million.
- Derivative Liabilities: The fair value of derivative liabilities related to contingent milestone payments decreased from $9.2 million at December 31, 2025, to $4.2 million at June 30, 2026. This reduction was due to the issuance of common stock to satisfy a $7.5 million milestone payment for the SGT-212 program.
- Share Count: Weighted average shares outstanding increased significantly due to equity issuances, rising from 94.1 million in Q2 2025 to 143.7 million in Q2 2026.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects current cash, cash equivalents, and available-for-sale securities ($377.7 million) to fund operations and capital expenditures into mid-2028. No debt is currently outstanding.
- Clinical Progress:
- SGT-003: The Phase 3 IMPACT DUCHENNE trial dosed its first participant in April 2026. The company plans to meet with the FDA in Q4 2026 to discuss the INSPIRE DUCHENNE data package and potential accelerated approval pathways.
- SGT-212: The Phase 1b FALCON trial dosed its first participant in January 2026. Two participants have been dosed with no treatment-related serious adverse events observed.
- SGT-501: The Phase 1b ARTEMIS trial is screening participants, with first dosing anticipated in the second half of 2026.
- Risks and Contingencies:
- Capital Requirements: The company expects to incur significant losses for the foreseeable future and will require additional funding beyond mid-2028 to continue operations.
- Regulatory Uncertainty: Risks include potential clinical holds, adverse events in trials, and evolving regulatory requirements for gene therapies (e.g., FDA guidance on diversity action plans).
- Manufacturing: Reliance on third-party contract development and manufacturing organizations (CDMOs) poses risks regarding supply chain, capacity, and quality control.
- Intellectual Property: Dependence on in-licensed patents and the risk of third-party infringement claims.
Key Facts for Investor Verification
- Verify the timeline and enrollment progress of the IMPACT DUCHENNE (Phase 3) and FALCON (Phase 1b) trials, as these are critical near-term catalysts.
- Monitor the company's cash burn rate relative to the stated runway into mid-2028, given the substantial increase in R&D spend.
- Review the terms of the March 2026 Private Placement and any subsequent ATM sales to assess dilution impact on existing shareholders.
- Track the status of the derivative liabilities associated with the FA212 asset acquisition, specifically the probability and timing of remaining milestone payments.
- Confirm the company's ability to secure manufacturing capacity for commercial-scale production of SGT-003, as this is a prerequisite for commercialization.